According to BioIntel360, the global gene editing technology market size is expected to record a CAGR of 21.5% during 2023-2027 to reach US$8,400.9 million by 2027, increasing from US$3,171.4 million...
According to BioIntel360, the global gene editing technology market size is expected to record a CAGR of 21.5% during 2023-2027 to reach US$8,400.9 million by 2027, increasing from US$3,171.4 million in 2023. Over the last five years, the sector has recorded a CAGR of 27.5% to reach US$2,488.3 million in 2022. Gene editing technology has emerged as one of the fastest-growing areas in the global healthcare sector. With the emerging technology showing immense potential to cure some of the world’s most feared diseases, including cancer, gene-editing technology can revolutionize the global healthcare landscape. Global gene editing market forecast reveals that the revolutionary CRISPR gene editing technology has sped its way from the lab to the clinical field within a span of a single decade. Notably, the CRISPR gene editing technology has turned out to be the founding stone of many innovative biotech start-ups, while also creating tens of billions of dollars in value. Looking at the potential of gene editing technology, big pharmaceutical players such as Bayer, Pfizer, and Regeneron have all shown interest in the space. Over the years, these firms have forged alliances with pioneers in the sector, with the hope to find treatment for life-limiting and life-threatening diseases, including cancer. Going forward, gene editing market trends show that these big corporations in the healthcare sector are expected to further continue with the trend of forging alliances with emerging start-ups, while also seeking buyout opportunities proactively, thereby allowing them to acquire tools to improve current treatments. Furthermore, big pharmaceutical giants are sitting on huge piles of cash and many of them are also in need to expand their product pipelines, as many of the patents would expire at the end of the ongoing decade. Consequently, every large pharmaceutical firm is expected to have some sort of gene editing capabilities, either through strategic collaborations or the acquisition of smaller firms. Some researchers have already started to make progress in the segment; however, global gene editing market analysis shows that it is expected to blow up over the next few years. Furthermore, research in the space will also expand the number of diseases that can be treated using the CRISPR gene editing technology. • The Somatic Cell Genome Editing (SCGE) Program, at the National Institutes of Health (NIH) has given 24 new funds to researchers in the United States and Canada to assist them. Over four years, this collection of SCGE Program awards will total about $89 million. Assuming finances are available, this raises the overall number of projects sponsored to 45 and the total financing to around $190 million over six years. Moreover, to ensure that gene editing-based medicine or treatment is available to the masses, firms need to focus on developing drugs that are not much expensive. While most of the trials are currently targeting rare diseases, therefore, the treatment of these diseases is also expensive, some biotech firms such as Verve Therapeutics have treated their first patient suffering from high cholesterol. The treatment, if successful, can be used in the market of millions of patients. Consequently, firms end to focus on diseases and treatments which can be provided to the masses and not just a handful of patients. Along with the healthcare sector, gene-editing technology is also expanding its roots in the agricultural market around the world. The need to ensure food security for their people has led several governments in enhancing their regulatory environment, thereby supporting the usage of gene-editing technology in the agricultural sector. Even European regulators, who have long opposed the implementation of gene editing technology for the production of crops, are also re-evaluating their viewpoint on the technology, to meet the growing food demand among people across Europe. Climate change and an unstable political environment have had a severe impact on the global production and availability of crops. Gene editing has shown the potential to develop climate-resistant and higher-yield crops. Consequently, the agricultural sector is another area of focus for biotech firms that are looking to drive growth in the gene editing market over the next few years. Looking at the growth potential of the sector, venture capital firms have invested billions of dollars in the space over the last few years, and the trend is expected to further continue from the short to medium-term perspective. As new areas of gene editing application emerge and breakthrough products are developed, the interest among venture capital firms, globally, is expected to balloon over the next three to four years. This will keep driving innovation and competitive landscape from the short to medium-term perspective, thereby supporting the gene editing market growth. This report presents an in-depth analysis of the current gene editing market scenario, with an emphasis on the future trajectory of potential opportunities in the gene editing industry. In addition to a combination of exhaustive secondary research along with primary research, BioIntel360’s research methodology leverages a proprietary predictive analytics platform to provide unbiased business intelligence. It provides a detailed analysis of gene editing market dynamics, covering clinical trials, patent data, financial deals, and company profiling details. It details market opportunities and risks across key segments – by technology, products, delivery method, disease, and applications. It also details market dynamics across various end-use sectors to assess emerging opportunities. In addition, this report provides analyst commentary on key trends, drivers, strategies, innovations, and regulations in gene editing technology market. This title from BioIntel360 provides global and regional insights along with data-centric analysis for the following 6 regions and 21 countries: • Global • North America o United States o Canada o Mexico • Europe o France o Germany o United Kingdom o Italy o Switzerland • Asia-Pacific o China o Japan o Australia o India o South Korea • Latin America o Brazil o Argentina o Colombia • MEA o Israel o South Africa o Turkey o UAE o Saudi Arabia
Insights and data in the report has been segmented under the following six modules: Module 1: Global Gene Editing Funding and Investments Outlook This module provides insights and data related to gene editing partnerships and investment (research and development, mergers and acquisitions, product development, commercialization, licensing, and manufacturing) and allows a peek into the futuristic trends of gene editing technology investment area. Module 2: Global Gene Editing Clinical Trial Data Assessment This module evaluates the data available from clinical trials conducted for various CRISPR, ZFNs, TALENs, and meganucleases-based therapies, representing a bird’s eye view of emerging market dynamics and risks in the gene editing sector. Module 3: Global Gene Editing Patent Data Analysis This module presents an exhaustive study of gene editing patent analytics (CRISPR, ZFN, TALENs, and meganucleases) at various levels, including strategic research planning as well as analyzing their potential applications. Module 4: Competitive Landscape This module provides detailed information along with a scoring matrix of key companies related to the gene editing industry, including their historical performance and the latest developments. Module 5: Global Gene Editing Market Size and Forecast This module provides projections on the market's development during the years 2018-2027 after the profound evaluation of market dynamics at the deeper segmentation level. This report also provides an in-depth, data-centric analysis of the global gene editing market at regional and country levels: By Technology • CRISPR CAS 9 • TALENs • ZFN • Others (Meganucleases) By Products • Kits & Enzymes (By CRISPR, TALENs, ZFN, Meganucleases) • Cell lines & Antibodies (By CRISPR, TALENs, ZFN, Meganucleases) • Plasmid & Controls (By CRISPR, TALENs, ZFN, Meganucleases) By Delivery Method • Ex-vivo • In-vivo By Disease/Disorders • Cancer • Blood Disorders (beta-thalassemia and sickle cell disease) • Blindness • Respiratory Disease (COVID-19 & Cystic fibrosis) • Others (AIDS, Huntington’s disease, Muscular dystrophy) By Application • Drug Development • Diagnostics • Plant Gene Editing • Others (Animal Gene Editing) By End-User • Pharmaceutical and Biopharmaceutical Companies • Biotechnology Companies • Contract Research Organisations • Academic Institutes and Research Centres By Regions • North America - U. S - Canada - Mexico • Europe - France - United Kingdom - Germany - Italy - Switzerland • Asia-Pacific - China - Japan - Australia - India - South Korea • MEA region - Israel - South Africa - Turkey - U.A. E - Saudi Arabia • Latin America - Brazil - Argentina Key Companies Covered • bluebird bio • Beam Therapeutics • Caribou Biosciences • Cellectis • Allogene Therapeutics • Intellia Therapeutics • Editas Medicine • Verve Therapeutics • AstraZeneca • Merck KGaA • Thermo Fisher Scientific Module 6 Regulatory Outlook This module contains a detailed understanding of the ethical, legal, and social implications of gene editing technology.
• Gene Editing Market Dynamics: Understand market opportunities and key trends along with forecast (2023-2027). Understand market dynamics across various segments such as by technology, products, delivery method, disease/disorders, application, geographical region, and company. • Competitive Landscape Analysis: Market position and snapshot of key players in the development of therapies based on CRISPR, meganucleases, TALENs, and ZFN. Each profile includes a brief overview of the company, information on its therapeutic pipeline, financial data (where available), the most recent events, and a knowledgeable prediction for the future. • Clinical Trial Analysis: Insights into Opportunity by a thorough evaluation of clinical trials involving various ZFNs, TALENs, and meganucleases-based therapies that have been completed or are still ongoing, using parameters such as trial status, trial registration year, an indication of the target disease, trial phase, patient enrolment, and sponsor/collaborator type. • Develop Market-Specific Strategies: Identify growth segments based on a thorough analysis of the CRISPR, ZFN, TALENs, and meganucleases patents that have been applied for or granted based on the patent type, the issuing agency, and patent offices involved, the Cooperative Patent Classification (CPC) symbols, the firm type, significant industry and non-industry participants (based on many patents), and discrete patent assignees. • Financial Deals Insights: Get Insights and information about various gene editing partnerships that have been developed, including those for research and development (R&D), clinical trials, mergers and acquisitions, product development, commercialization, licencing, and manufacturing. A complete analysis of the various investments made in companies that specialise in developing drugs using CRISPR, ZFNs, TALENs, and meganucleases.
This market intelligence report features an in-depth analysis on the current market dynamics of gene editing technologies such as CRISPR/Cas9, ZFNs, TALENs, and Meganucleases. It provides a detailed analysis of gene editing market dynamics, covering clinical trials, patent data, financial deals, and competitive landscape through 40+ sections, 1091 tables, and 1467 charts. Chapter: 1 About this Report 1.1 Research Methodology 1.2 Definitions 1.3 Disclaimer Chapter: 2 Gene Editing Market Dynamics 2.1 Introduction 2.2 Global Gene Editing Technology Market Outlook and Future Growth Dynamics 2.2.1 Market Opportunities and Growth Dynamics 2.2.2 Strategy and Innovations 2.2.3 Regulation and Challenges Related to Gene Editing Around the Globe 2.3 Regulatory Dynamics Assessment Across Different regions 2.3.1 North America Gene Editing Regulations 2.3.2 Europe Gene Editing Regulations 2.3.3 Asia Pacific Gene Editing Regulations 2.3.4 Middle East & Africa region Gene Editing Regulation 2.3.5 Latin America Gene Editing Regulations Chapter: 3 Global Gene Editing Technology Discovery and Clinical Pipeline Market Attractiveness 3.1 CRISPR Based: Discovery and Clinical Pipeline 3.2 TALEN Based: Discovery and Clinical Pipeline 3.3 ZFNs Based: Discovery and Clinical Pipeline 3.4 Meganucleases Based: Discovery and Clinical Pipeline Chapter: 4 Gene Editing Technology Financial Deals & Alliances: Analysis of Emerging Market Dynamics & Outlook, 2018-2027 4.1 Gene Editing Technology Financial Deals Market Size and Forecast, 2018-2027 4.2 Gene Editing Technology Financial Deals Vs Mergers & Acquisition, 2021 vs 2024 4.3 Gene Editing Technology Financial Deals Analysis by Application, 2021 vs 2024 4.4 Gene Editing Technology Financial Deals Analysis by Diseases, 2021 vs 2024 4.5 Gene Editing Technology Financial Deals Analysis by Region, 2021 vs 2024 4.6 Gene Editing Financial Deals Analysis by Type of Technology, 2021 vs 2024 4.7 Gene Editing Technology Financial Deals Analysis by End-Use Sector, 2021 vs 2024 4.8 Gene Editing Technology Financial Deals by Fundings and Investment 4.8.1 Gene Editing Technology Funding and Investment Annual Analysis, 2018-2027 4.8.2 Gene Editing Technology Funding and Investment by Year, Growth Rate (%) 4.8.3 Gene Editing Technology Funding Analysis by Geographical Regions 4.8.4 Gene Editing Technology: Funding Analysis by Type of Industry Players 4.8.5 Gene Editing Technology: Funding Analysis by Therapeutics 4.8.6 Gene Editing Technology Type of Funding Analysis 4.9 Key Financial Deals & Alliances - Recent List of Major Acquisition and Mergers 4.10 North America Region Financial Deals 4.11 Europe Region Financial Deals Chapter: 5 Gene Editing Technology Patent Analysis & Outlook 5.1 Gene Editing Technology Patent Analysis & Outlook, 2018-2027 5.2 Gene Editing Technology: Patent Players Overview 5.3 Gene Editing Technology: White Space Mapping Analysis 5.4 Gene Editing Technology: Keyword Search Expressions 5.5 Gene Editing Technology: Type of Innovation Analysis 5.6 Gene Editing Technology: Type of Innovation Futuristic Analysis 5.7 Gene Editing Technology: CRISPR Top Patent Owners Benchmarking Analysis 5.8 Gene Editing Technology: TALENs Top Patent Owners Benchmarking Analysis 5.9 Gene Editing Technology: ZFNs Top Patent Owners Benchmarking Analysis 5.10 Gene Editing Technology: Patent Valuation Analysis 5.11 Gene Editing Technology: Scope of Innovation Analysis 5.12 Gene Editing Technology Scope of Innovation FTO Analysis 5.13 Trends Associated with Legal Status: Gene Editing Technology 5.14 Patent Filing Velocity Analysis: Gene Editing Technology 5.15 Trends Associated with Investors: Gene Editing Technology 5.16 Trends Associated with Top Applicants: Gene Editing Technology 5.17 CPC Code Classification Analysis of Patents by Type of Gene Editing Technology 5.18 Geographical Distribution of Patents by Type of Gene Editing Technology 5.19 Key Recent Patents by Gene Editing Technology Chapter: 6 Clinical Trial Analysis & Outlook, 2017-2027 6.1 Global Gene Editing Technology: Clinical Trial Region-wise Prediction & Estimation, 2018-2027 6.2 Clinical Trial Analysis by Key Countries 6.3 Clinical Trial Analysis by Disease / Disorder 6.4 Gene Editing Technology Clinical Trial Phase-wise Analysis 6.5 Gene Editing Technology Clinical Trial Status Analysis 6.6 Gene Editing Technology Clinical Trial Study-type Analysis 6.7 Snapshot of Key Clinical Trials Chapter: 7 Gene Editing Technology Competitive Landscape Analysis: Key Company Profiles and Strategic Initiatives 7.1 Gene Editing Competitive Index Ranking & Attractiveness Quadrant 7.2 Gene Editing Technology: Competitive Analysis Quadrant 7.3 Gene Editing Competitive Landscape by End Markets 7.4 Key Companies by Regions 7.5 Competitive Landscape by Type of Gene Editing Technology 7.6 Company Profiling 7.7 CRISPR Therapeutics AG 7.8 bluebird bio 7.9 Beam Therapeutics 7.10 Caribou Biosciences 7.11 Cellectis 7.12 Allogene Therapeutics 7.13 Intellia Therapeutics Inc. 7.14 Editas Medicine 7.15 Verve Therapeutics 7.16 AstraZeneca 7.17 Merck KGaA 7.18 Thermo Fisher Scientific Inc. Chapter: 8 Gene Editing Technology Market Size and Forecast, 2018-2027 8.1 Gene Editing Technology Market Share by Technology (%), 2018-2027 8.1.1 Gene Editing Technology Market Size and Forecast by CRISPR, 2018-2027 8.1.2 Gene Editing Technology Market Size and Forecast by TALENs, 2018-2027 8.1.3 Gene Editing Technology Market Size and Forecast by ZFNs, 2018-2027 8.1.4 Gene Editing Technology Market Size and Forecast by Meganucleases, 2018-2027 8.2 Gene Editing Technology Market Share by CRISPR Product (%), 2018-2027 8.2.1 Gene Editing Technology Market Size and Forecast by Vector Based Cas9, 2018-2027 8.2.2 Gene Editing Technology Market Size and Forecast by DNA Free Cas9, 2018-2027 8.2.3 Gene Editing Technology Market Size and Forecast by Libraries & Antibodies, 2018-2027 8.2.4 Gene Editing Technology Market Size and Forecast by gRNA Design and Vector Construction, 2018-2027 8.2.5 Gene Editing Technology Market Size and Forecast by Cell Lines & Engineering, 2018-2027 8.2.6 Gene Editing Technology Market Size and Forecast by Others (Plasmid, Controls), 2018-2027 8.3 Gene Editing Technology Market Share by TALENs Product (%), 2018-2027 8.3.1 Gene Editing Technology Market Size and Forecast by Kits & Enzymes, 2018-2027 8.3.2 Gene Editing Technology Market Size and Forecast by Cell lines & Antibodies, 2018-2027 8.3.3 Gene Editing Technology Market Size and Forecast by Others (Plasmid, Controls), 2018-2027 8.4 Gene Editing Technology Market Share by ZFNs Product (%), 2018-2027 8.4.1 Gene Editing Technology Market Size and Forecast by Kits & Enzymes, 2018-2027 8.4.2 Gene Editing Technology Market Size and Forecast by Cell lines & Antibodies, 2018-2027 8.4.3 Gene Editing Technology Market Size and Forecast by Others (Plasmid, Controls), 2018-2027 8.5 Gene Editing Technology Market Share by Meganucleases Product (%), 2018-2027 8.5.1 Gene Editing Technology Market Size and Forecast by Kits & Enzymes, 2018-2027 8.5.2 Gene Editing Technology Market Size and Forecast by Cell lines & Antibodies, 2018-2027 8.5.3 Gene Editing Technology Market Size and Forecast by Others (Plasmid, Controls), 2018-2027 8.6 Gene Editing Technology Market Share by Delivery Mode (%), 2018-2027 8.6.1 Gene Editing Technology Market Size and Forecast by Ex-vivo, 2018-2027 8.6.2 Gene Editing Technology Market Size and Forecast by In-vivo, 2018-2027 8.7 Gene Editing Technology Market Share by Disease/Disorders (%), 2018-2027 8.7.1 Gene Editing Technology Market Size and Forecast by Cancer, 2018-2027 8.7.2 Gene Editing Technology Market Size and Forecast by Blood Disorders, 2018-2027 8.7.3 Gene Editing Technology Market Size and Forecast by Blindness, 2018-2027 8.7.4 Gene Editing Technology Market Size and Forecast by Respiratory Disease, 2018-2027 8.7.5 Gene Editing Technology Market Size and Forecast by Others, 2018-2027 8.8 Gene Editing Technology Market Share by Application (%), 2018-2027 8.8.1 Gene Editing Technology Market Size and Forecast by Drug Development, 2018-2027 8.8.2 Gene Editing Technology Market Size and Forecast by Diagnostics, 2018-2027 8.8.3 Gene Editing Technology Market Size and Forecast by Plant Gene Editing, 2018-2027 8.8.4 Gene Editing Technology Market Size and Forecast by Animal Gene Editing, 2018-2027 8.9 Gene Editing Technology Market Share by End User (%), 2018-2027 8.9.1 Gene Editing Technology Market Size and Forecast by Pharmaceutical and Biopharmaceutical Companies, 2018-2027 8.9.2 Gene Editing Technology Market Size and Forecast by Biotechnology Companies, 2018-2027 8.9.3 Gene Editing Technology Market Size and Forecast by Contract Research Organisations, 2018-2027 8.9.4 Gene Editing Technology Market Size and Forecast by Academic Institutes and Research Centres, 2018-2027 Chapter 9- Chapter 39: This section contains chapters providing gene editing market sizing and forecast for additional 21 countries and 6 regions.
This report includes 1091 tables across various sections covering global, regional, and country level analysis. Due to space constraints, limited number of tables have been displayed here. Table 1: Gene Editing Technology Financial Deals Market Size and Forecast, by Value (USD Million), 2018-2027 Table 2: Gene Editing Technology Funding and Investment by Value (USD Million), 2018-2027 Table 3: Recent list of CRISPR Technology Patents Table 4: Recent list of TALENs Technology Patents Table 5: Recent list of ZFN Technology Patents Table 6: Recent list of Meganucleases Technology Patents Table 7: Gene Editing Technology Market Size by Value (USD Million), 2018-2027 Table 8: Gene Editing Technology Market Size by CRISPR by Value (USD Million), 2018-2027 Table 9: Gene Editing Technology Market Size by TALENs by Value (USD Million), 2018-2027 Table 10: Gene Editing Technology Market Size by ZFNs by Value (USD Million), 2018-2027 Table 11: Gene Editing Technology Market Size by Meganucleases by Value (USD Million), 2018-2027 Table 12: Gene Editing Technology Market Size by Vector Based Cas9 by Value (USD Million), 2018-2027 Table 13: Gene Editing Technology Market Size by DNA Free Cas9 by Value (USD Million), 2018-2027 Table 14: Gene Editing Technology Market Size by Libraries & Antibodies by Value (USD Million), 2018-2027 Table 15: Gene Editing Technology Market Size by gRNA Design and Vector Construction by Value (USD Million), 2018-2027 Table 16: Gene Editing Technology Market Size by Cell Lines & Engineering by Value (USD Million), 2018-2027 Table 17: Gene Editing Technology Market Size by Others (Plasmid, Controls) by Value (USD Million), 2018-2027 Table 18: Gene Editing Technology Market Size by Kits & Enzymes by Value (USD Million), 2018-2027 Table 19: Gene Editing Technology Market Size by Cell lines & Antibodies by Value (USD Million), 2018-2027 Table 20: Gene Editing Technology Market Size by Others (Plasmid, Controls) by Value (USD Million), 2018-2027 Table 21: Gene Editing Technology Market Size by Kits & Enzymes by Value (USD Million), 2018-2027 Table 22: Gene Editing Technology Market Size by Cell lines & Antibodies by Value (USD Million), 2018-2027 Table 23: Gene Editing Technology Market Size by Others (Plasmid, Controls) by Value (USD Million), 2018-2027 Table 24: Gene Editing Technology Market Size by Kits & Enzymes by Value (USD Million), 2018-2027 Table 25: Gene Editing Technology Market Size by Cell lines & Antibodies by Value (USD Million), 2018-2027 Table 26: Gene Editing Technology Market Size by Others (Plasmid, Controls) by Value (USD Million), 2018-2027 Table 27: Gene Editing Technology Market Size by Ex-vivo by Value (USD Million), 2018-2027 Table 28: Gene Editing Technology Market Size by In-vivo by Value (USD Million), 2018-2027 Table 29: Gene Editing Technology Market Size by Cancer by Value (USD Million), 2018-2027 Table 30: Gene Editing Technology Market Size by Blood Disorders by Value (USD Million), 2018-2027 Table 31: Gene Editing Technology Market Size by Blindness by Value (USD Million), 2018-2027 Table 32: Gene Editing Technology Market Size by Respiratory Disease by Value (USD Million), 2018-2027 Table 33: Gene Editing Technology Market Size by Others by Value (USD Million), 2018-2027 Table 34: Gene Editing Technology Market Size by Drug Development by Value (USD Million), 2018-2027 Table 35: Gene Editing Technology Market Size by Diagnostics by Value (USD Million), 2018-2027 Table 36: Gene Editing Technology Market Size by Plant Gene Editing by Value (USD Million), 2018-2027 Table 37: Gene Editing Technology Market Size by Animal Gene Editing by Value (USD Million), 2018-2027 Table 38: Gene Editing Technology Market Size by Pharmaceutical and Biopharmaceutical Companies by Value (USD Million), 2018-2027 Table 39: Gene Editing Technology Market Size by Biotechnology Companies by Value (USD Million), 2018-2027 Table 40: Gene Editing Technology Market Size by Contract Research Organisations by Value (USD Million), 2018-2027 Table 41: Gene Editing Technology Market Size by Academic Institutes and Research Centres by Value (USD Million), 2018-2027 Table 42 – 1091: For more information, please contact us on info@biointel360.com
This report includes 1467 figures across various sections covering global, regional, and country-level analysis. Due to space constraints, the limited number of figures have been displayed here. Figure 1: BioIntel360’s Research Methodology Figure 2: Historical Events: Gene Editing Technology Figure 3: CRISPR Based: Cancer Therapeutics Discovery and Clinical Pipeline Figure 4: CRISPR Based: Blood Therapeutics Discovery and Clinical Pipeline Figure 5: CRISPR Based: Blood Therapeutics Discovery and Clinical Pipeline Figure 6: CRISPR Based: Bacterial Infection Therapeutics Discovery and Clinical Pipeline Figure 7: CRISPR Based: Eye Therapeutics Discovery and Clinical Pipeline Figure 8: TALENs Based: Cancer Therapeutics Discovery and Clinical Pipeline Figure 9: ZFNs Based: Metabolic Disorders Therapeutics Discovery and Clinical Pipeline Figure 10: Meganucleases Based: Cancer Therapeutics Discovery and Clinical Pipeline Figure 11: Gene Editing Technology Financial Deals Market Size and Forecast, by Value (USD Million), 2018-2027 Figure 12: Global Gene Editing – Partnership Vs Mergers & Acquisition Analysis, 2021 vs 2024 Figure 13: Global Gene Editing Financial Deals – Analysis by Application, 2021 vs 2024 Figure 14: Global Gene Editing Financial Deals – Analysis by Diseases, 2021 vs 2024 Figure 15: Global Gene Editing Financial Deals – Analysis by Region, 2021 vs 2024 Figure 16: Global Gene Editing Financial Deals – Analysis by Technology, 2021 vs 2024 Figure 17: Global Gene Editing Financial Deals – Analysis by End Users, 2017 vs 2024 Figure 18: Gene Editing Technology Funding and Investment annually analysis, by Value (USD Million), 2018-2027 Figure 19: Gene Editing Technology Funding and Investment, by Year Growth Rate (%) 2018-2027 Figure 20: Gene Editing Technology Funding and Investment, by Geographical Regions 2021 vs 2024 Figure 21: Gene Editing Technology Funding and Investment, by Type of Industry Players, 2021 vs 2024 Figure 22: Gene Editing Technology Funding and Investment, by Therapeutics, 2021 vs 2024 Figure 23: Gene Editing Technology Funding Analysis, by Type of Funding, 2021 Figure 24: Recent List of Major Acquisitions and Mergers Figure 25: Recent North America Region Financial Deals/Partnerships Figure 26: Recent European Region Financial Deals/Partnerships Figure 27: Gene Editing Technology Historical and Futuristic Trend – Patent Granted 2018-2027 Figure 28: Patent Distribution by Industry Players and Non-Industry Players Figure 29: Gene Editing Technology CPC Code White Space Analysis Figure 30: Gene Editing Technology CRISPR Keyword Search Expressions Figure 31: Gene Editing Technology TALENs Keyword Search Expressions Figure 32: Gene Editing Technology ZFNs Keyword Search Expressions Figure 33: Gene Editing Technology Patent Analysis by Type of Innovation, 2021 Figure 34: Gene Editing Technology Type of Innovation Futuristics Analysis, 2021 vs 2024 Figure 35: Gene Editing Technology – Massachusetts Institute of Technology and their CPC classification code analysis Figure 36: Gene Editing Technology – The Broad Institute INC and their CPC classification code analysis Figure 37: Gene Editing Technology – President and Fellows of Harvard College and their CPC classification code analysis Figure 38: Gene Editing Technology – Howard Hughes Medical Institute and their CPC classification code analysis Figure 39: Gene Editing Technology – The Brigham and Women’s Hospital INC and their CPC classification code analysis Figure 40: Gene Editing Technology – Benson Hill Seeds INC and their CPC classification code analysis Figure 41: Gene Editing Technology – Sakata Seed Corporation and their CPC classification code analysis Figure 42: Gene Editing Technology – Massachusetts Institute of Technology and their CPC classification code analysis Figure 43: Gene Editing Technology – Hmclause INC and their CPC classification code analysis Figure 44: Gene Editing Technology – Corteva Agriscience LLC and their CPC classification code analysis Figure 45: Gene Editing Technology – Sangamo Therapeutics INC and their CPC classification code analysis Figure 46: Gene Editing Technology – Hmclause INC and their CPC classification code analysis Figure 47: Gene Editing Technology – Regeneron Pharmaceuticals INC and their CPC classification code analysis Figure 48: Gene Editing Technology – Regents of the University of California and their CPC classification code analysis Figure 49: Gene Editing Technology – University of Massachusetts and their CPC classification code analysis Figure 50: Gene Editing Technology – Patent Valuation Analysis Figure 51: Gene Editing Technology – Patent Documents Comparison Based on Parameters Figure 52: Most Valuable Patent Examples Figure 53: Gene Editing Technology – Scope of Innovation Analysis Figure 54: Gene Editing Technology FTO Analysis Based on Scope of Innovation Figure 55: Gene Editing – CRISPR Patent Trends Associated with Legal Status 2017-2022 Figure 56: Gene Editing – TALENs Patent Trends Associated with Legal Status 2017-2022 Figure 57: Gene Editing – ZFNs Patent Trends Associated with Legal Status 2017-2022 Figure 58: Gene Editing – Meganucleases Patent Trends Associated with Legal Status 2017-2022 Figure 59: Gene Editing – CRISPR Technology Patent Published Status Analysis, 2017-2022 Figure 60: Gene Editing – TALENs Technology Patent Published Status Analysis, 2017-2022 Figure 61: Gene Editing – ZFNs Technology Patent by Published Status Analysis, 2017-2022 Figure 62: Gene Editing – Meganucleases Technology Patent by Published Status Analysis, 2017-2022 Figure 63: Gene Editing – CRISPR Technology Patent by Investors Analysis, 2017-2022 Figure 64: Gene Editing – TALENs Technology Patent by Investors Analysis, 2017-2022 Figure 65: Gene Editing – ZFNs Technology Patent by Investors Analysis, 2017-2022 Figure 66: Gene Editing – Meganucleases Technology Patent by Investors Analysis, 20217-2022 Figure 67: Gene Editing – CRISPR Technology Patent by Top Applicants Analysis, 2017-2022 Figure 68: Gene Editing – TALENs Technology Patent by Top Applicants Analysis, 2017-2022 Figure 69: Gene Editing – ZFNs Technology Patent by Top Applicants Analysis, 2017-2022 Figure 70: Gene Editing – Meganucleases Technology Patent by Top Applicants Analysis, 2017-2022 Figure 71: Gene Editing – CRISPR Technology Patent Top CPC Classification Code, 2017-2022 Figure 72: Gene Editing – TALENs Technology Patent Top CPC Classification Code, 2017-2022 Figure 73: Gene Editing – ZFNs Technology Patent Top CPC Classification Code, 2017-2022 Figure 74: Gene Editing – Meganucleases Technology Patent Top CPC Classification Code, 2017-2022 Figure 75: Gene Editing – CRISPR Technology Patent Documents by Jurisdiction, 2017-2022 Figure 76: Gene Editing – TALENs Technology Patent Documents by Jurisdiction, 2017-2022 Figure 77: Gene Editing – ZFNs Technology Patent Documents by Jurisdiction, 2017-2022 Figure 78: Gene Editing – Meganucleases Technology Patent Documents by Jurisdiction, 2017-2022 Figure 79: Gene Editing – Clinical Trial Region-wise Forecast Analysis, 2017-2027 Figure 80: Gene Editing – CRISPR Clinical Trial Country-wise Analysis Figure 81: Gene Editing – TALENs Clinical Trial Country-wise Analysis Figure 82: Gene Editing – ZFNs Clinical Trial Country-wise Analysis Figure 83: Gene Editing – CRISPR Clinical Trial Disease-wise Analysis, 2021 vs 2024 Figure 84: Gene Editing – TALENs Clinical Trial Disease-wise Analysis, 2021 vs 2024 Figure 85: Gene Editing – ZFNs Clinical Trial Disease-wise Analysis, 2021 vs 2024 Figure 86: Gene Editing – CRISPR Clinical Trial Phase-wise Analysis, 2021 vs 2024 Figure 87: Gene Editing – TALENs Clinical Trial Phase-wise Analysis, 2021 vs 2024 Figure 88: Gene Editing – ZFNs Clinical Trial Phase-wise Analysis, 2021 vs 2024 Figure 89: Gene Editing – CRISPR Clinical Trial Status Analysis Figure 90: Gene Editing – TALENs Clinical Trial Status Analysis Figure 91: Gene Editing – ZFNs Clinical Trial Status Analysis Figure 92: Gene Editing – CRISPR Clinical Trial Study-type Analysis Figure 93: Gene Editing – TALENs Clinical Study-type Analysis Figure 94: Gene Editing – ZFNs Clinical Study-type Analysis Figure 95: Recent CRISPR Clinical Trial List Figure 96: Recent TALENs Clinical Trial List Figure 97: Recent ZFNs Clinical Trial List Figure 98: Gene Editing Technology Companies Competitive Landscape Figure 99: Gene Editing Technology Companies Mapping Quadrant Figure 100: Gene Editing Technology Companies by End Users Figure 101: Gene Editing Technology Companies by Geography Figure 102: Gene Editing Technology Companies by Different Technology Figure 103: Gene Editing Technology Companies by Market Domain Figure 104: Gene Editing Technology Market Size by Value (USD Million), 2018-2027 Figure 105: Gene Editing Technology Market Share by Technology (%), 2018-2027 Figure 106: Gene Editing Technology Market Size by CRISPR by Value (USD Million), 2018-2027 Figure 107: Gene Editing Technology Market Size by TALENs by Value (USD Million), 2018-2027 Figure 108: Gene Editing Technology Market Size by ZFNs by Value (USD Million), 2018-2027 Figure 109: Gene Editing Technology Market Size by Meganucleases by Value (USD Million), 2018-2027 Figure 110: Gene Editing Technology Market Share by CRISPR Product (%), 2018-2027 Figure 111: Gene Editing Technology Market Size by Vector Based Cas9 by Value (USD Million), 2018-2027 Figure 112: Gene Editing Technology Market Size by DNA Free Cas9 by Value (USD Million), 2018-2027 Figure 113: Gene Editing Technology Market Size by Libraries & Antibodies by Value (USD Million), 2018-2027 Figure 114: Gene Editing Technology Market Size by gRNA Design and Vector Construction by Value (USD Million), 2018-2027 Figure 115: Gene Editing Technology Market Size by Cell Lines & Engineering by Value (USD Million), 2018-2027 Figure 116: Gene Editing Technology Market Size by Others (Plasmid, Controls) by Value (USD Million), 2018-2027 Figure 117: Gene Editing Technology Market Share by TALENs Product (%), 2018-2027 Figure 118: Gene Editing Technology Market Size by Kits & Enzymes by Value (USD Million), 2018-2027 Figure 119: Gene Editing Technology Market Size by Cell lines & Antibodies by Value (USD Million), 2018-2027 Figure 120: Gene Editing Technology Market Size by Others (Plasmid, Controls) by Value (USD Million), 2018-2027 Figure 121: Gene Editing Technology Market Share by ZFNs Product (%), 2018-2027 Figure 122: Gene Editing Technology Market Size by Kits & Enzymes by Value (USD Million), 2018-2027 Figure 123: Gene Editing Technology Market Size by Cell lines & Antibodies by Value (USD Million), 2018-2027 Figure 124: Gene Editing Technology Market Size by Others (Plasmid, Controls) by Value (USD Million), 2018-2027 Figure 125: Gene Editing Technology Market Share by Meganucleases Product (%), 2018-2027 Figure 126: Gene Editing Technology Market Size by Kits & Enzymes by Value (USD Million), 2018-2027 Figure 127: Gene Editing Technology Market Size by Cell lines & Antibodies by Value (USD Million), 2018-2027 Figure 128: Gene Editing Technology Market Size by Others (Plasmid, Controls) by Value (USD Million), 2018-2027 Figure 129: Gene Editing Technology Market Share, By Delivery Mode, 2018-2027 Figure 130: Gene Editing Technology Market Size by Ex-vivo by Value (USD Million), 2018-2027 Figure 131: Gene Editing Technology Market Size by In-vivo by Value (USD Million), 2018-2027 Figure 132: Gene Editing Technology Market Share by Diseases/Disorders (%), 2018-2027 Figure 133: Gene Editing Technology Market Size by Cancer by Value (USD Million), 2018-2027 Figure 134: Gene Editing Technology Market Size by Blood Disorders by Value (USD Million), 2018-2027 Figure 135: Gene Editing Technology Market Size by Blindness by Value (USD Million), 2018-2027 Figure 136: Gene Editing Technology Market Size by Respiratory Disease by Value (USD Million), 2018-2027 Figure 137: Gene Editing Technology Market Size by Others by Value (USD Million), 2018-2027 Figure 138: Gene Editing Technology Market Share by Applications (%), 2018-2027 Figure 139: Gene Editing Technology Market Size by Drug Development by Value (USD Million), 2018-2027 Figure 140: Gene Editing Technology Market Size by Diagnostics by Value (USD Million), 2018-2027 Figure 141: Gene Editing Technology Market Size by Plant Gene Editing by Value (USD Million), 2018-2027 Figure 142: Gene Editing Technology Market Size by Animal Gene Editing by Value (USD Million), 2018-2027 Figure 143: Gene Editing Technology Market Share by End Users (%), 2018-2027 Figure 144: Gene Editing Technology Market Size by Pharmaceutical and Biopharmaceutical Companies by Value (USD Million), 2018-2027 Figure 145: Gene Editing Technology Market Size by Biotechnology Companies by Value (USD Million), 2018-2027 Figure 146: Gene Editing Technology Market Size by Contract Research Organisations by Value (USD Million), 2018-2027 Figure 147: Gene Editing Technology Market Size by Academic Institutes and Research Centres by Value (USD Million), 2018-2027 Figure 148 – 1467: For more information, please contact us on info@biointel360.com
